ArticlePloS one2021
Outcomes of kidney transplantation over a 16-year period in Korea: An analysis of the National Health Information Database.
Article in PloS one, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.
- Predictor factor for worse outcomes in kidney transplant recipients infected with coronavirus disease 2019: A systematic review and meta-analysis.Transplant immunology · 2023Pooled it
- Long-Term Mortality and Causes of Death After Kidney and Liver Transplantation: A Nationwide Population-Based Cohort Study in South Korea.Journal of clinical medicine · 2026Article
- Urinary endotrophin as a biomarker for T cell-mediated rejection-associated fibrogenesis in kidney transplant recipients.Clinical kidney journal · 2025Article
- Impact of sirolimus on long-term adverse cardiovascular outcomes in kidney transplant recipients: A nationwide cohort study.European journal of clinical investigation · 2025Article
- Novel association between graft rejection and post-transplant malignancy in solid organ transplantation.World journal of transplantation · 2025Article
- Complications Associated with Immunosuppressive Agents in Solid Organ Transplant Recipients: A Nationwide Analysis.Journal of clinical medicine · 2025Article
- Evaluation of efficacy and safety of generic tacrolimus (SuprotacEuropean journal of translational myology · 2025Article
- Time-dependent impact of immunosuppressant regimens on cardiovascular outcomes in kidney transplant recipients: a nationwide cohort study.Frontiers in pharmacology · 2025Article
- Report on post-transplantation cancer in southeast Asia from the Thai kidney transplantation cohort.Scientific reports · 2024Article
- Impact of Induction Immunosuppressants on T Lymphocyte Subsets after Kidney Transplantation: A Prospective Observational Study with Focus on Anti-Thymocyte Globulin and Basiliximab Induction Therapies.International journal of molecular sciences · 2023Observational
- Associations of Perioperative Red Blood Cell Transfusion With Outcomes of Kidney Transplantation in Korea Over a 16-Year Period.Journal of Korean medical science · 2023Article
- Characteristics of stroke after liver and kidney transplantation.Frontiers in neurology · 2023Article
- Pregnancy outcomes after living kidney donation from a nationwide population-based cohort study from Korea.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study investigated the outcomes of kidney transplantation (KT) over a 16-year period in Korea and identified risk factors for graft failure using a nationwide population-based cohort.
methodsWe investigated the Korean National Health Insurance Service-National Health Information Database. Health insurance claims for patients who underwent KT between 2002 and 2017 were analyzed.
resultsThe data from 18,331 patients who underwent their first KT were reviewed. The percentage of antithymocyte globulin (ATG) induction continuously increased from 2.0% in 2002 to 23.5% in 2017. Rituximab began to be used in 2008 and had increased to 141 patients (9.6%) in 2013. Acute rejection occurred in 17.3% of all patients in 2002 but decreased to 6.3% in 2017. The rejection-free survival rates were 78.8% at 6 months after KT, 76.1% after 1 year, 67.5% after 5 years, 61.7% after 10 years, and 56.7% after 15 years. The graft survival rates remained over 80% until 12 years after KT, and then rapidly decreased to 50.5% at 16 years after KT. In Cox's multivariate analysis, risk factors for graft failure included being male, more recent KT, KT from deceased donor, use of ATG, basiliximab, or rituximab, tacrolimus use as an initial calcineurin inhibitor, acute rejection history, and cytomegalovirus infection.
conclusionsATG and rituximab use has gradually increased in Korea and more recent KT is associated with an increased risk of graft failure. Therefore, meticulous preoperative evaluation and postoperative management are necessary in the case of recent KT with high risk of graft failure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.